What one share of Apimeds Pharmaceuticals Us holds
Corporation”). As a result of the Merger, MindWave became a direct wholly owned subsidiary of the Company. At the Effective
Apimeds Pharmaceuticals Us’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$40.29 |
|---|---|
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | −$9.23 |
| Cash and investments | $0.18 |
| Debt | $8.48 |
| Book value | $70.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1.69 | — | — | — | $0.04 |
| 2024 | — | −$1.76 | — | — | — | −$1.72 |
| 2025 | — | −$5.51 | $0.05 | −$8.26 | — | $121.88 |
Common questions about Apimeds Pharmaceuticals Us
How much does one share of Apimeds Pharmaceuticals Us earn?
Over the last 12 months, Apimeds Pharmaceuticals Us lost $40.29 for each share.
Does Apimeds Pharmaceuticals Us pay a dividend?
Apimeds Pharmaceuticals Us didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Apimeds Pharmaceuticals Us’s book value per share?
Apimeds Pharmaceuticals Us’s book value is $70.54 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Apimeds Pharmaceuticals Us have?
Each share of Apimeds Pharmaceuticals Us has $0.18 of cash and investments and $8.48 of debt, as of June 30, 2026.
What is Apimeds Pharmaceuticals Us’s free cash flow per share?
−$9.23 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.